Back to search results

MRI Imaging for Brain Cancer (Glioma)

This study is looking at how advanced Magnetic Resonance Imaging (MRI) can help doctors find high-risk areas in brain tumors (malignant gliomas). The researchers believe this imaging might better predict which parts of a tumor are likely to grow back, even after standard treatments like chemotherapy and radiation. The goal is to see if this advanced MRI is safe and causes few or mild side effects. You might be able to join if you are 18 or older and have a suspected or confirmed diagnosis of high-grade or low-grade glioma, or a tumor suspected to have a specific genetic change (IDH mutation), and may receive radiation therapy. The study aims to see if these MRI changes can predict tumor progression.

Study design
This is an interventional study with a planned enrollment of 135 participants. It is not randomized, meaning all participants will receive the advanced MRI.
What's involved
You would receive advanced MRI scans before radiation treatment, about two months after treatment, and then about every two months for the duration of the study.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the duration of the study, with MRI scans taken about every two months after the initial post-treatment scan.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00870129

Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

Recruiting
NAAges 18+InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~135 participants
Updated 2025-10-10 on ClinicalTrials.gov
What's tested:MRI and advanced MRI sequences

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess the utility of baseline advanced MRI & changes between baseline & follow up advanced MRI in predicting high risk areas that are likely to develop progressive glioma despite chemoradiotherapy.
Measured over 1 -7 weeks before radiation treatment, about two months after treatment, and about every two months thereafter for the duration of the study.

Conditions

Brain Cancer
Glioma

Explore related trials

GliomaIDH1 wt Allele

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Robert Young, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Robert Young, MD
212-639-8196
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Suspected or Histopathologically proven diagnosis of high grade or low glioma or tumor is suspected to harbor an isocitrate dehydrogenase (IDH) mutation
May undergo radiation therapy
Patient and/or guardian is able to provide written informed consent prior to study registration
Age ≥ 18 years old

Exclusion

Extreme claustrophobia that precludes MRI scan
Known allergic reaction to Gd-DTPA
Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines
Any absolute contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander).
Pregnant or nursing female
Unable to cooperate for MRI and/or radiation therapy planning

What this trial measures

  • To assess the utility of baseline advanced MRI & changes between baseline & follow up advanced MRI in predicting high risk areas that are likely to develop progressive glioma despite chemoradiotherapy.1 -7 weeks before radiation treatment, about two months after treatment, and about every two months thereafter for the duration of the study.